Site search
Correspondence address
310 Mira Street, Stavropol, Russia, 355017
Tel
+7 865 2352511, +7 865 2353229.
E-mail
medvestnik@stgmu.ru
The journal is included into The list of leading scientific periodicals.
The journal is included into VINITI database and is registered in Electronic scientific library.
The journal is indexed by SCOPUS, Ulrich's International Periodicals Directory.
[Abstracts]
Galina Nerodo; Oksana Kravtsova; Vera Nikitina; Ekaterina Verenikina; Ivan Nikitin;
Ovarian cancer is an extremely aggressive and unpredictable disease that affects women of all ages. We compared morphological structures of malignant serous ovarian tumors and the results of treatment in a group without chemotherapy and after neoadjuvant chemotherapy regimens: CAP and CMFV. The study included patients with stage III–IV disease, identical in degree of malignant process, age, general condition and histological structure of the tumor. Neoadjuvant chemotherapy for serous ovarian cancer according to the SAR scheme, in comparison with the CMFV scheme, leads to a significant improvement in the immediate results of treatment, increased operability and improved long-term results. Five-year survival of patients after neoadjuvant chemotherapy under the CAP scheme was 68 %, according to the CMFV scheme – 16 %.
References:
1. Kedrova A. G., Levakov S. A., Krasilnikov S. E., Maksimenko T. A., Voznesenskiy V. I., Gerasimov A. V., Astakhov D. A., Kosyy V. V., Nechaeva O.E. Opukholi zhenskoy reproduktivnoy sistemy. – Tumors of female reproductive system. 2016;12(1):85-93.
2. Nerodo G. A., Novikova I. A., Zlatnik E. Yu., Ardzha A. Yu. Fundamentalnye issledovaniya. – Fundamental research. 2015;1(8):1649-1654.
3. Nerodo G. A., Ushakova N. D., Goroshinskaya I. A., Mkrtchyan E. T., Menshenina A. P. Izvestiya vysshikh uchebnykh zavedeniy. Severo-Kavkazskiy region. Estestvennye nauki. – University news. North-Caucasian region. Natural sciences series. 2014;1(179):98-102.
4. Armstrong D. K., Bundy B., Wenzel L., Huang H. Q., Baergen R., Lele S., Copeland L. J., Walker J. L., Burger R. A. N. Engl. J. Med. 2006;354:34-43. doi: 10.1056/ NEJMoa052985
5. Bookman M. A., Brady M. F., McGuire W. P., Harper P. G., Alberts D. S., Friedlander M., Colombo N., Fowler J. M., Argenta P. A., De Geest K., Mutch D. G., Burger R. A., Swart A. M., Trimble E. L., Accario-Winslow C., Roth L. M. J. Clin. Oncol. 2009;27(9):1419-1425. doi: 10.1200/JCO.2008.19.1684
6. Fujiwara K., Nagao S., Kigawa J., Noma J., Akamatsu N., Miyagi Y., Numa F., Okada M., Aotani E. Int J Gynecol Cancer. 2009;19(5):834-837. doi:10.1111/IGC.0b013e3181a29dfe
Keywords: serous ovarian cancer, chemotherapy, treatment outcomes